Q4 2022 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Good afternoon, ladies and gentlemen. Welcome to the Sartorius and Sartorius Stedim Biotech conference call on the preliminary full year 2022 results. Today's conference is being recorded.
At this time, I would like to turn the conference over to Dr. Joachim Kreuzburg, CEO. Please go ahead, sir.
Thank you very much. Happy New Year, everyone, and welcome to our today's conference call on the preliminary results of the year 2022 for both Sartorius AG as well as the Sartorius Stedim Biotech. Thank you for your interest. Together with Rainer, our CFO, I will kick it off. We will first talk about the results of the Sartorius Group and then later on those of Sartorius Stedim Biotech. Let me start with a brief overview on the most important results for 2022. It has been another successful year after 2 years of very dynamic growth. We have been able to grow both divisions double digit. Overall, we met the targets that we tried to achieve, even though the Corona
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |